{
    "organizations": [],
    "uuid": "b80b2481137e1bc2db1eee388140b97db952803b",
    "author": "",
    "url": "https://www.reuters.com/article/brief-axsome-therapeutics-says-its-cns-d/brief-axsome-therapeutics-says-its-cns-disorder-candidate-axs-09-met-main-goal-of-phase-1-trial-idUSASB0C7D9",
    "ord_in_thread": 0,
    "title": "BRIEF-Axsome Therapeutics Says Its CNS Disorder Candidate AXS-09 Met Main Goal Of Phase 1 Trial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 26, 2018 / 12:13 PM / Updated 9 minutes ago BRIEF-Axsome Therapeutics Says Its CNS Disorder Candidate AXS-09 Met Main Goal Of Phase 1 Trial Reuters Staff 1 Min Read Feb 26 (Reuters) - Axsome Therapeutics Inc: * AXSOME THERAPEUTICS ANNOUNCES PRIMARY ENDPOINT MET IN PHASE 1 TRIAL OF NEXT GENERATION PRODUCT CANDIDATE AXS-09 CONTAINING CHIRALLY PURE ESBUPROPION AND DEXTROMETHORPHAN * AXSOME THERAPEUTICS INC - ‍CHIRALLY PURE AND STABLE SINGLE ENANTIOMERS OF BUPROPION ACHIEVED​ * AXSOME THERAPEUTICS INC - ‍AXS-09 WAS WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS REPORTED IN TRIAL​ * AXSOME THERAPEUTICS INC - ‍ AXS-09 RESULTS IN SUBSTANTIAL INCREASES IN DEXTROMETHORPHAN PLASMA LEVELS​ Source text for Eikon: Further company coverage:",
    "published": "2018-02-26T14:13:00.000+02:00",
    "crawled": "2018-02-26T14:26:06.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "updated",
        "minute",
        "ago",
        "therapeutic",
        "say",
        "cns",
        "disorder",
        "candidate",
        "met",
        "main",
        "goal",
        "phase",
        "trial",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "axsome",
        "therapeutic",
        "inc",
        "axsome",
        "therapeutic",
        "announces",
        "primary",
        "endpoint",
        "met",
        "phase",
        "trial",
        "next",
        "generation",
        "product",
        "candidate",
        "containing",
        "chirally",
        "pure",
        "esbupropion",
        "dextromethorphan",
        "axsome",
        "therapeutic",
        "inc",
        "pure",
        "stable",
        "single",
        "enantiomer",
        "bupropion",
        "axsome",
        "therapeutic",
        "inc",
        "well",
        "tolerated",
        "serious",
        "adverse",
        "event",
        "reported",
        "axsome",
        "therapeutic",
        "inc",
        "result",
        "substantial",
        "increase",
        "dextromethorphan",
        "plasma",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}